- Home
- DGICA vs ALT Comparison
DGICA vs ALT Comparison
Compare DGICA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICA | ALT |
|---|---|---|
| Founded | 1986 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.2M | 573.8M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DGICA | ALT |
|---|---|---|
| Price | $18.06 | $2.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $21.00 | $17.11 |
| AVG Volume (30 Days) | 89.5K | ★ 3.1M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $978,014,322.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.82 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $16.11 | $2.56 |
| 52 Week High | $21.06 | $6.44 |
Technical Indicators
Market Signals| Indicator | DGICA | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 33.86 | 34.73 |
| Support Level | $16.43 | $2.80 |
| Resistance Level | $19.54 | $3.35 |
| Average True Range (ATR) | 0.41 | 0.12 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 10.34 | 3.28 |
Price Performance
Historical ComparisonAbout DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.